Bright Minds Biosciences Files 6-K with Press Release
Ticker: DRUG · Form: 6-K · Filed: Oct 3, 2024 · CIK: 1827401
Sentiment: neutral
Topics: filing, sec, press-release
Related Tickers: BMBS
TL;DR
BMBS filed a 6-K with a press release on Oct 3rd. Keep an eye out for updates.
AI Summary
Bright Minds Biosciences Inc. filed a Form 6-K on October 3, 2024, to report information as a foreign private issuer. The filing includes a press release dated October 3, 2024, as Exhibit 99.1. The company is incorporated in A1 and its fiscal year ends on September 30.
Why It Matters
This filing indicates that Bright Minds Biosciences is providing updated information to the SEC, which could include material developments relevant to investors.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain specific financial or operational disclosures that would immediately indicate high risk.
Key Players & Entities
- BRIGHT MINDS BIOSCIENCES INC. (company) — Filer
- October 3, 2024 (date) — Filing date and press release date
- 001-40997 (other) — SEC File Number
- 19 Vestry Street New York, NY 10013 (address) — Principal executive office
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report information as a foreign private issuer, including a press release dated October 3, 2024.
What exhibit is included with this Form 6-K?
Exhibit 99.1, a Press Release dated October 3, 2024, is submitted with this Form 6-K.
What is the SEC file number for Bright Minds Biosciences Inc.?
The SEC file number for Bright Minds Biosciences Inc. is 001-40997.
When does Bright Minds Biosciences Inc.'s fiscal year end?
Bright Minds Biosciences Inc.'s fiscal year ends on September 30.
Where is the principal executive office of Bright Minds Biosciences Inc. located?
The principal executive office of Bright Minds Biosciences Inc. is located at 19 Vestry Street, New York, NY 10013.
Filing Stats: 148 words · 1 min read · ~1 pages · Grade level 11.6 · Accepted 2024-10-03 11:36:59
Filing Documents
- f6k_100324.htm (6-K) — 4KB
- exh_991.htm (EX-99.1) — 9KB
- 0001171843-24-005482.txt ( ) — 14KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Bright Minds Biosciences Inc. Date: October 3, 2024 /s/ Ryan Cheung Ryan Cheung Chief Financial Officer